InvestSMART

Cynata Therapeutics Limited (ASX:CYP)

ALERT: Price-sensitive ASX Announcement for CYP
Current share price for CYP : $0.012 -0.333 (-96.52%)+
Announcement
Release
29 Jan 2026 9:30AM
Price at Release
$0.345
Full Release
download
Summary
Cynata Therapeutics Limited reported its December 2025 quarterly activities and provided an Appendix 4C cash flow report. The company continues to make advancements in its clinical trials, particularly with its Cymerus™ iPSC-derived MSC products. Cynata's CYP-001 demonstrated significant success in a Phase 1 trial for aGvHD, and results from its Phase 3 osteoarthritis trial and Phase 2 aGvHD trial are expected in Q2 2026. The company maintains a robust intellectual property portfolio and has secured additional funding through a $1.712m R&D Tax Incentive Refund and a $1.204m ATM facility. Cynata closed the quarter with $2.588m in cash, estimating 4.5 quarters of funding availability, and remains committed to clinical progress and regulatory engagement.
Key Points
  • Cynata Therapeutics Limited reported its December 2025 quarterly activities and Appendix 4C.
  • The company's Cymerus™ iPSC-derived MSC product, CYP-001, was highlighted for its success in a Phase 1 trial for aGvHD with significant patient responses.
  • Cynata anticipates results from its Phase 3 osteoarthritis trial of CYP-004 and Phase 2 aGvHD trial in Q2 2026.
  • The company's intellectual property portfolio includes several patents related to their stem cell technologies.
  • Cynata received a $1.712m R&D Tax Incentive Refund and raised $1.204m through its ATM facility.
  • The company closed the quarter with $2.588m in cash and estimates 4.5 quarters of funding availability.
  • Cynata remains focused on advancing its clinical programs, engaging with regulatory authorities, and managing its capital effectively.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.